In this interview, Dr. Margaret Faul discusses her current research, outlines her vision and goals for the journal in 2025 and beyond, and shares advice for young researchers in the field.
On January 1, 2025, Dr. Margaret Faul, Ph.D., Vice President of Drug Substance Technologies at Amgen and Site Head of Amgen Massachusetts, was appointed as Editor-in-Chief of Organic Process Research & Development (OPR&D). Dr. Faul took leadership of OPR&D following the successful tenure of Kai Rossen, Ph.D., who had served as Editor-in-Chief since 2015.
OPR&D serves as an essential communication tool between industrial chemists and chemists working in universities and research institutes. As such the journal reports original work from the broad field of industrial process chemistry and chemical engineering but also presents academic results that are relevant to industrial applications.
Expand each section of the interview below to learn more about Dr. Faul's current research, her goals for OPR&D in 2025 and beyond, and her advice for young researchers in the field.
